Overall, the benefit of therapeutic intervention directed towards p53 will be taken into consideration only if there are specific mutations or dysregulations in the p53 pathway leading to a hypothesized restored tumor-suppressive function of the mutated p53 that increases the overall responsiveness to treatment. The gene discussed is TP53; the disease is neoplasm.